Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis

Br J Dermatol. 2017 Sep;177(3):879-881. doi: 10.1111/bjd.15656. Epub 2017 Aug 9.

¹ Oregon Medical Research Center, Portland, OR, U.S.A.
² Dermatologikum Hamburg and SCIderm Research Institute, Hamburg, Germany.
³ The Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester Academic Health Science Centre, Manchester, U.K.
⁴ Department of Dermatology, Venereology, and Allergology, Wroclaw Medical University, Wroclaw, Poland.
⁵ Department of Dermatology, Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
⁶ University of Texas Health Science Center at Houston and Center for Clinical Studies, Houston, TX, U.S.A.
⁷ Novartis Pharma AG, Basel, Switzerland.
⁸ Novartis Healthcare Pvt. Ltd, Hyderabad, India.
⁹ Dalhousie University, Halifax, NS, Canada.

No abstract available

Publication types